Sobi Q3 EBIT tops estimates by 14%, lifts full-year guidance after Vonjo hit
PositiveFinancial Markets

Sobi has reported a strong third-quarter performance, with EBIT exceeding estimates by 14%. This impressive result has led the company to raise its full-year guidance, reflecting confidence in its growth trajectory. The success is largely attributed to the positive reception of its product Vonjo, which has significantly contributed to revenue. This news is important as it highlights Sobi's resilience and potential for continued success in the competitive pharmaceutical market.
— Curated by the World Pulse Now AI Editorial System